FDA's draft guidance on developing drugs for community acquired bacterial pneumonia marks a complete reversal of policies enacted in the early 2000s and codified in a 2009 guidance document.

According to clinicians and biopharma researchers, the new draft guidance is a triumph of clinical pragmatism over statistical purity that will make it easier to develop new drugs for CABP.